---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-24-035102"
form_type: "8-K"
ticker: "AIXC"
cik: "0001460702"
company_name: "AIxCrypto Holdings, Inc."
filed_at: "2024-09-05T23:59:59+00:00"
generated_at: "2026-05-31T06:13:58.140762+00:00"
event_type: "other_material"
sentiment: "negative"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Qualigen Therapeutics prices $3.46M public offering of common stock and pre-funded warrants

## Summary
- Offering: 14,724,058 shares at $0.13 each and pre-funded warrants for 11,972,754 shares at $0.129 per warrant.
- Gross proceeds ~$3.46M; closing expected September 6, 2024.
- Net proceeds to accelerate payment of $2M Senior Note from July 2024 and fund operations.
- Also for clinical/preclinical studies, working capital, possible Marizyme expansion, and acquisitions.
- Univest Securities acted as exclusive placement agent.

## SEC filing metadata
- accession: 0001493152-24-035102
- form_type: 8-K
- ticker: AIXC
- cik: 0001460702
- company_name: AIxCrypto Holdings, Inc.
- filed_at: 2024-09-05T23:59:59+00:00
- event_type: other_material
- sentiment: negative
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1460702/000149315224035102/0001493152-24-035102-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1460702/000149315224035102/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-24-035102
- JSON: https://secwatch.observer/filing/0001493152-24-035102.json
- Plain text: https://secwatch.observer/filing/0001493152-24-035102.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.